By Sabrina Valle (Reuters) -Bankrupt U.S. pharmacy chain Rite Aid on Thursday said it agreed to sell more than 1,000 stores in separate transactions to CVS Pharmacy, Walgreens, Albertsons, Kroger and Giant Eagle, among others. CVS Pharmacy will buy and operate many Rite Aid and Bartell Drugs stores in Washington, Oregon and Idaho, the company said in a filing. Rite Aid stores will remain open, and customers can continue to use pharmacy services, including prescription refills and immunizations, without interruption, it said. Walgreens declined to comment. The other bidders did not immediately respond to requests for comment. Earlier this month, Rite Aid filed for bankruptcy for the second time in less than two years, after poor performance in its retail business made it difficult for the company to maintain sufficient cash flow and restock its retail inventory. The company has received court approval to pursue a rapid-fire sale of its pharmacy business, with the company aiming to reach agreements with buyers and get a sale approved in two weeks. Under the sale procedures approved by U.S. Bankruptcy Judge Michael Kaplan, Rite Aid would seek final approval of one or more sales at a May 21 court hearing. The Pennsylvania-based company entered bankruptcy with over $2 billion in debt and has warned employees about likely job cuts. Bloomberg had previously reported on CVS' bid. (Reporting by Sabrina Valle in New York and Christy Santhosh in Bengaluru; additional reporting by Dietrich Knauth and Juveria Tabassum; Editing by Leroy Leo and Cynthia Osterman) View Comments
Rite Aid to sell 1,000 stores to CVS, Walgreens and others
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...